Amiodarone induces cell proliferation and myofibroblast differentiation via ERK1/2 and p38 MAPK signaling in fibroblasts
-
Add time:09/07/2019 Source:sciencedirect.com
Amiodarone is a potent antidysrhythmic agent that can cause potentially life-threatening pulmonary fibrosis. Accumulating evidence has demonstrated that myofibroblast differentiation is related to the pathogenesis of pulmonary fibrosis. In the present study, we treated human embryonic lung fibroblasts (HELFs) with amiodarone, and investigated the relative molecular mechanism of amiodarone-induced pulmonary fibrosis and pathway determinants PD98059 (extracellular signal-regulated kinase (ERK) inhibitor) and SB203580 (p38 mitogen-activated protein kinase (MAPK) inhibitor). Cell proliferation was assessed by Cell Counting Kit-8 (CCK-8). The secretion of collagen Ⅰ was detected by ELISA. The expressions of α-smooth muscle actin (α-SMA), vimentin, phosphorylated ERK1/2 (p-ERK1/2), ERK1/2, phosphorylated p38 MAPK (p-p38), and p38 MAPK were investigated using Western blot analysis. The levels of α-SMA and vimentin were also determined by immunofluorescence and qRT-PCR. We report that amiodarone promoted cell proliferation and collagen Ⅰ secretion, induced α-SMA and vimentin protein and mRNA expression accompanied by increased phosphorylation of ERK1/2 and p38 MAPK, and furthermore, PD98059 and SB203580 remarkably reduced the proliferative response of HELFs compared with amiodarone group and greatly attenuated α-SMA, vimentin and collagen Ⅰ protein production induced by amiodarone. Taken together, our study suggests that amiodarone regulates cell proliferation and myofibroblast differentiation in HELFs through modulating ERK1/2 and p38 MAPK pathways, and these signal pathways may therefore represent an attractive treatment modality in amiodarone-induced pulmonary fibrosis.
We also recommend Trading Suppliers and Manufacturers of Amiodarone hydrochloride (cas 19774-82-4). Pls Click Website Link as below: cas 19774-82-4 suppliers
Prev:Original articleStability study of Amiodarone hydrochloride (cas 19774-82-4) in capsules for paediatric patients using a high-performance liquid chromatography methodÉtude de stabilité des gélules de chlorhydrate d’amiodarone à usage pédiatrique par chromatographie liquide à haute performance
Next:Short communicationQuality by design (QbD) based development and validation of an HPLC method for Amiodarone hydrochloride (cas 19774-82-4) and its impurities in the drug substance) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Case report – Special issue: Panvascular medicine“Blue-grey syndrome” – A rare adverse effect of amiodarone09/09/2019
- Short communicationQuality by design (QbD) based development and validation of an HPLC method for Amiodarone hydrochloride (cas 19774-82-4) and its impurities in the drug substance09/08/2019
- Original articleStability study of Amiodarone hydrochloride (cas 19774-82-4) in capsules for paediatric patients using a high-performance liquid chromatography methodÉtude de stabilité des gélules de chlorhydrate d’amiodarone à usage pédiatrique par chromatographie liquide à haute performance09/06/2019
- Original articleOptimized and validated spectrophotometric methods for the determination of Amiodarone hydrochloride (cas 19774-82-4) in commercial dosage forms using N-bromosuccinimide and bromothymol blue09/05/2019
- Solubility of Amiodarone hydrochloride (cas 19774-82-4) in aqueous co-solvent mixtures revisited: IBKI preferential solvation analysis09/04/2019
- Utilization of ultrasonic-assisted RESOLV (US-RESOLV) with polymeric stabilizers for production of Amiodarone hydrochloride (cas 19774-82-4) nanoparticles: Optimization of the process parameters09/03/2019
- Solubility of an antiarrhythmic drug (Amiodarone hydrochloride (cas 19774-82-4)) in supercritical carbon dioxide: Experimental and modeling09/02/2019
-
Health and Chemical more >


